Colon to Rectum

Gut. 2023;72(4):663–70

Faye AS, Højgaard Allin K, Iversen AT, Agrawal M, Faith J, Colombel JF, Jess T

Antibiotic use as a risk factor for inflammatory bowel disease across the ages: A population-based cohort study


Background: There is an increasing incidence of inflammatory bowel disease (IBD) for which environmental factors are suspected. Antibiotics have been associated with development of IBD in earlier generations, but their influence on IBD risk in adults is uncertain.
Objective: To assess the impact of antibiotic exposure, including dose-response, timing and antibiotic class, on the risk of IBD in all individuals aged ≥ 10 years.
Design: Using Denmark nationwide registries, a population-based cohort of residents aged ≥ 10 years was established between 2000 and 2018. Incidence rate ratios (IRRs) for IBD following antibiotic exposure were calculated using Poisson regression.
Results: There were a total of 6,104,245 individuals, resulting in 87,112,328 person-years of follow-up, and 52,898 new cases of IBD. Antibiotic exposure was associated with an increased risk of IBD as compared with no antibiotic exposure for all age groups, although was greatest among individuals aged 40−60 years and ≥ 60 years (age 10−40 years, IRR = 1.28, 95% confidence interval [CI]: 1.25−1.32; age 40−60 years, IRR = 1.48, 95% CI: 1.43−1.54; age ≥ 60 years, IRR = 1.47, 95% CI: 1.42−1.53). For all age groups a positive dose-response was observed, with similar results seen for both ulcerative colitis and Crohn’s disease. The highest risk of developing IBD was seen 1−2 years after antibiotic exposure, and after use of antibiotic classes often prescribed to treat gastrointestinal pathogens.

Conclusion: Antibiotic exposure is associated with an increased risk of inflammatory bowel disease, and was highest among individuals aged 40 years and older. This risk increased with cumulative antibiotic exposure, with antibiotics targeting gastrointestinal pathogens and within 1−2 years after antibiotic exposure.

A.S. Faye, M.D., Assistant Professor, Departments of Medicine and Population Health, NYU Langone Health, New York, NY, USA,
E-Mail: ad-am.faye@nyulangone.org

DOI: 10.1136/gutjnl-2022-327845

Back to overview

this could be of interest:

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomized, double-blind, controlled, phase 2, proof-of-concept trial

Lancet Gastroenterol Hepatol. 2023;8(4):307–20

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomized, double-blind, placebo-controlled, phase 3 studies

Lancet. 2023;401(10383):1159–71

More articles on the topic